AR and posterior cortical atrophy: Despite the development of multiple new therapies over the past two decades, including taxane chemotherapies, androgen receptor (AR) signaling inhibitors (ARSIs), poly ADP-ribose polymerase (PARP) inhibitors, and radionuclide therapy, treatment resistance is inevitable and advanced PCa remains lethal.2